• The “Glycosylation Analysis Services Market, 2021-2030” report

    Roots Analysis has announced the addition of “Glycosylation Analysis Services Market, 2021 – 2030” report to its list of offerings.

    For more information , please visit https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    The “Glycosylation Analysis Services Market, 2021-2030” report Roots Analysis has announced the addition of “Glycosylation Analysis Services Market, 2021 – 2030” report to its list of offerings. For more information , please visit https://www.rootsanalysis.com/reports/glycosylation-analysis-services-market.html
    Glycosylation Analysis Services Market 2021-2030 | Market Size | Industry Analysis | 2030
    Glycosylation Analysis Services Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million

    Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

    Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/310/request-sample.html

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
     More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
     An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters
     A detailed assessment of the current market landscape of BBB penetrant drugs.
     Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.
     An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.
     Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.
     An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.
     An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.
     An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).
     An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.
     An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
     An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.
     A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.
     A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.
     An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.
    A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :
     Type of Payment Model Adopted
     Upfront payments
     Milestone payments

     Type of Molecule
     Small Molecules
     Biologics

     Target Disease Indication
     Brain Metastases in Breast Cancer
     Glioblastoma Multiforme
     Hunter Syndrome
     Hurler Syndrome

     Leading Technology Platforms
     G®-Technology
     J-Brain Cargo® Technology
     LRP-1 Technology
     Trojan Horse Technology

     Leading Drug Developers
     2-BBB
     Angiochem
     ArmaGen
     JCR Pharmaceuticals

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific

    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
     Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
     Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
     Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
     Mathias Schmidt (Chief Executive Officer, ArmaGen)
     Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
     Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
     Carole Desseaux (Head of Clinical Affairs, CarThera)
     Jamal Temsamani (Head of Drug Development, Vect-Horus)
     Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

    Key companies covered in the report
     Angiochem
     ArmaGen
     BioArctic
     Cyclenium Pharma
     Denali Therapeutics
     ICB International
     Iproteos
     JCR Pharmaceuticals
     Lauren Sciences
     Medesis Pharma
     Ossianix
     Vect-Horus

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
    2. DNA-Encoded Libraries: Platforms and Services Market
    3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions. Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.” To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/310/request-sample.html The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:  More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs  An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters  A detailed assessment of the current market landscape of BBB penetrant drugs.  Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.  An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.  Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.  An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.  An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.  An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).  An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.  An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.  An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.  A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.  A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.  An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :  Type of Payment Model Adopted  Upfront payments  Milestone payments  Type of Molecule  Small Molecules  Biologics  Target Disease Indication  Brain Metastases in Breast Cancer  Glioblastoma Multiforme  Hunter Syndrome  Hurler Syndrome  Leading Technology Platforms  G®-Technology  J-Brain Cargo® Technology  LRP-1 Technology  Trojan Horse Technology  Leading Drug Developers  2-BBB  Angiochem  ArmaGen  JCR Pharmaceuticals  Key Geographical Regions  North America  Europe  Asia-Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companies  Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))  Frank S Walsh (Chief Executive Officer and Founder, Ossianix)  Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)  Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)  Mathias Schmidt (Chief Executive Officer, ArmaGen)  Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)  Xavier Rivero (Chief Operating Officer, Sagetis Biotech)  Carole Desseaux (Head of Clinical Affairs, CarThera)  Jamal Temsamani (Head of Drug Development, Vect-Horus)  Kevin Kit Parker (Professor, Wyss Institute, Harvard University) Key companies covered in the report  Angiochem  ArmaGen  BioArctic  Cyclenium Pharma  Denali Therapeutics  ICB International  Iproteos  JCR Pharmaceuticals  Lauren Sciences  Medesis Pharma  Ossianix  Vect-Horus For additional details, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development 2. DNA-Encoded Libraries: Platforms and Services Market 3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Blood-Brain Barrier (BBB) | Industry Analysis | Market Size | 2030
    Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics Nanoparticle based Approaches)
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The biopharmaceutical excipient manufacturing market is projected to grow at an annualized rate of 5.8%

    The demand for biopharmaceutical excipients has grown considerably in the past few years; they play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs)

    Roots Analysis has announced the addition of “Biopharmaceutical Excipient Market” report to its list of offerings

    Owing to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. In order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are anticipated to expand their capabilities and existing capacities in the coming years.

    To order this 200+ page report, which features 75+ figures and 110+ tables, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html

    Key Market Insights

    Over 40 companies, across the world, claim to offer biopharmaceutical excipients
    Majority of the firms (34%) engaged in this domain are mid-sized players, followed by large firms (32%) and very large companies (19%). Close to 30% of the stakeholders were established post 2000. Further, 37% players are based in North America; within this region, the US emerged as a most prominent hub.

    Partnership activity within this domain has grown at a CAGR of 70%, between 2016 and 2021
    Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%).

    ~ 40% rise in expansion initiatives in this field, during the period 2016-2021
    More than 45% of such initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of expansion initiatives (78%) were carried out in Europe and North America.

    Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing
    The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe.

    North America and Europe are anticipated to capture over 70% of the market share, by 2035
    In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market.

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html

    Key Questions Answered
     Who are the key players engaged in biopharmaceutical excipient manufacturing?
     Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?
     What type of partnership models are commonly adopted by stakeholders in this industry?
     What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?
     What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The financial opportunity within the protein design and engineering services market has been analyzed across the following segments:

     Type of Biologic
     Antibodies
     Vaccines
     Cell and Gene Therapies
     Other Biologics

     Type of Excipient
     Carbohydrates
     Polymers
     Solubilizers / Surfactants
     Polyols
     Proteins / Amino Acids
     Others

     Company Size
     Small
     Mid-Sized
     Large / Very Large

     Scale of Operation
     Preclinical
     Clinical
     Commercial

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Latin America
     MENA
     Rest of the World

    The report also features inputs from eminent industry stakeholders, according to whom, growing demand for biopharmaceutical excipients will drive the growth of manufacturers engaged in the biopharmaceutical excipient manufacturing domain, in the coming future.

    The research includes profiles of key players (listed below); each profile features a brief overview of the company, financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.
     ABITEC
     Avantor
     BASF
     Corden Pharma
     DFE Pharma
     Evonik
     Kirsch Pharma
     Merck KGaA
     Pfanstiehl
     Roquette
     Spectrum Chemical Manufacturing
     SPI Pharma

    For additional details, please visit
    https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html
    or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Gene Editing beyond CRISPR Market: Industry Trends and Global Forecasts, 2022-2035
    2. Cell and Gene Therapy Bioassay Services Market: Industry Trends and Global Forecasts, 2022-2035
    3. Thermostable Vaccines and Thermostable Biologics Market: Industry Trends and Global Forecasts, 2021-2035
    4. Protein Design and Engineering Market: Industry Trends and Global Forecasts, 2021-2035
    5. Next Generation Sequencing (NGS) Kits Market: Industry Trends and Global Forecast, 2021-2035

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The biopharmaceutical excipient manufacturing market is projected to grow at an annualized rate of 5.8% The demand for biopharmaceutical excipients has grown considerably in the past few years; they play a critical role in biologics development by enhancing the solubility and bioavailability, controlling pH and tonicity of the active pharmaceutical ingredients (APIs) Roots Analysis has announced the addition of “Biopharmaceutical Excipient Market” report to its list of offerings Owing to the highly complex and capital-intensive manufacturing processes of biopharmaceutical excipients, many contemporary biologic developers prefer to rely on CMOs for the supply of GMP grade excipients. In order to cater to the growing demand for biopharmaceutical excipients across both clinical and commercial scales, CMOs with expertise in this field are anticipated to expand their capabilities and existing capacities in the coming years. To order this 200+ page report, which features 75+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html Key Market Insights Over 40 companies, across the world, claim to offer biopharmaceutical excipients Majority of the firms (34%) engaged in this domain are mid-sized players, followed by large firms (32%) and very large companies (19%). Close to 30% of the stakeholders were established post 2000. Further, 37% players are based in North America; within this region, the US emerged as a most prominent hub. Partnership activity within this domain has grown at a CAGR of 70%, between 2016 and 2021 Over 40 agreements have been inked in the last 5 years in this domain; 32% of which were distribution agreements. Other popular types of partnership models adopted by players engaged in this domain include acquisitions (23%) and supply agreements (13%). ~ 40% rise in expansion initiatives in this field, during the period 2016-2021 More than 45% of such initiatives were focused on capacity expansion of manufacturing facilities, followed by those undertaken for expanding existing facilities (43%). It is worth mentioning that most of expansion initiatives (78%) were carried out in Europe and North America. Approximately 95% of the total installed capacity is dedicated to commercial scale manufacturing The remaining 5% of the installed capacity is focused on preclinical / clinical scale manufacturing of biopharmaceutical excipients. In addition, over 50% of the total current global, installed biopharmaceutical excipient manufacturing capacity is installed in Europe. North America and Europe are anticipated to capture over 70% of the market share, by 2035 In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (6.4%) in the long term. Further, in 2035, biopharmaceutical excipient manufacturing market for antibodies is expected to capture the majority share (~52%) of the total market. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html Key Questions Answered  Who are the key players engaged in biopharmaceutical excipient manufacturing?  Which global regions are considered as key hubs for biopharmaceutical excipient manufacturing?  What type of partnership models are commonly adopted by stakeholders in this industry?  What kind of expansion initiatives have been undertaken by biopharmaceutical excipient manufacturers?  What is current, global biopharmaceutical excipient manufacturing capacity of contract manufacturers?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the protein design and engineering services market has been analyzed across the following segments:  Type of Biologic  Antibodies  Vaccines  Cell and Gene Therapies  Other Biologics  Type of Excipient  Carbohydrates  Polymers  Solubilizers / Surfactants  Polyols  Proteins / Amino Acids  Others  Company Size  Small  Mid-Sized  Large / Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  MENA  Rest of the World The report also features inputs from eminent industry stakeholders, according to whom, growing demand for biopharmaceutical excipients will drive the growth of manufacturers engaged in the biopharmaceutical excipient manufacturing domain, in the coming future. The research includes profiles of key players (listed below); each profile features a brief overview of the company, financial information (if available), details related to its biopharmaceutical excipients portfolio, manufacturing facilities, recent developments, and an informed future outlook.  ABITEC  Avantor  BASF  Corden Pharma  DFE Pharma  Evonik  Kirsch Pharma  Merck KGaA  Pfanstiehl  Roquette  Spectrum Chemical Manufacturing  SPI Pharma For additional details, please visit https://www.rootsanalysis.com/reports/biopharmaceutical-excipient-manufacturing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Gene Editing beyond CRISPR Market: Industry Trends and Global Forecasts, 2022-2035 2. Cell and Gene Therapy Bioassay Services Market: Industry Trends and Global Forecasts, 2022-2035 3. Thermostable Vaccines and Thermostable Biologics Market: Industry Trends and Global Forecasts, 2021-2035 4. Protein Design and Engineering Market: Industry Trends and Global Forecasts, 2021-2035 5. Next Generation Sequencing (NGS) Kits Market: Industry Trends and Global Forecast, 2021-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Excipient Manufacturing Market | Industry Analysis | Market Size | 2030
    Biopharmaceutical Excipient Manufacturing Market report features an extensive study of the current market landscape and future opportunity for the players involved in the development of clinical trials software...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The nuclear medicine and radiopharmaceutical manufacturing market is estimated to be more than USD 6 billion in 2030

    The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030”

    The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:
     A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals.
     An insightful four-dimensional comparison of the radiopharmaceutical manufacturers.
     Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players).
     An analysis of recent partnerships and collaborations inked in this domain since 2017.
     A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m).
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Target Therapeutic Area
     Cardiology
     Neurology
     Oncology
     Thyroid
     Others
     Application Area
     Diagnostic
     Therapeutic
     Type of Diagnostic Radiopharmaceuticals
     PET
     SPECT
     Type of Therapeutic Radiopharmaceuticals
     Alpha Emitters
     Beta Emitters
     Others
     Purpose of Production
     In-House
     Outsourcing
     Key Geographical Region
     North America
     Europe
     Asia-Pacific and the Rest of the World

    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     J James Davis, Vice President Quality / R&D, Shertech Laboratories
     Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School
     Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen
     Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
     Anonymous, ITM Isotopen Technologien München

    Key companies covered in the report
     Advanced Accelerator Applications
     Belgian Nuclear Research Center (SCK•CEN)
     Cardinal Health
     China Isotope & Radiation Corporation
     Curium Pharma
     DuChemBio
     Eckert & Ziegler
     Eczacibasi-Monrol
     GE Healthcare
     Jubilant DraxImage
     Lantheus Medical Imaging
     Nihon Medi-Physics
     Nordion
     PETNET Solutions
     SinoTau Pharmaceuticals
     SOFIE

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html

    Other Recent Offerings
    1. High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030
    2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030
    4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The nuclear medicine and radiopharmaceutical manufacturing market is estimated to be more than USD 6 billion in 2030 The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030” The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:  A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals.  An insightful four-dimensional comparison of the radiopharmaceutical manufacturers.  Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players).  An analysis of recent partnerships and collaborations inked in this domain since 2017.  A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m).  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Target Therapeutic Area  Cardiology  Neurology  Oncology  Thyroid  Others  Application Area  Diagnostic  Therapeutic  Type of Diagnostic Radiopharmaceuticals  PET  SPECT  Type of Therapeutic Radiopharmaceuticals  Alpha Emitters  Beta Emitters  Others  Purpose of Production  In-House  Outsourcing  Key Geographical Region  North America  Europe  Asia-Pacific and the Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies  J James Davis, Vice President Quality / R&D, Shertech Laboratories  Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School  Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen  Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology  Anonymous, ITM Isotopen Technologien München Key companies covered in the report  Advanced Accelerator Applications  Belgian Nuclear Research Center (SCK•CEN)  Cardinal Health  China Isotope & Radiation Corporation  Curium Pharma  DuChemBio  Eckert & Ziegler  Eczacibasi-Monrol  GE Healthcare  Jubilant DraxImage  Lantheus Medical Imaging  Nihon Medi-Physics  Nordion  PETNET Solutions  SinoTau Pharmaceuticals  SOFIE For more information please click on the following link: https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html Other Recent Offerings 1. High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030 2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030 4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Nuclear Medicine and Radiopharmaceuticals Manufacturing Market | Market Size | 2030
    Market research report on nuclear medicine and radiopharmaceuticals manufacturing with a focus on current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030

    Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

    Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

    Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

    To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html.

    Key Market Insights

    70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma
    Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.

    Around 65% of the therapeutics are being developed as small molecules
    Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.

    More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market
    North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders.

    Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered
    More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active.

    Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020
    About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma.

    More than 260 articles have been published related to soft tissue sarcoma, since January 2021
    Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus.

    Around 75 eminent scientists were identified as key opinion leaders (KOLs)
    65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities.

    North America is anticipated to capture over 70% of the global market share in 2030
    In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030.

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html

    Key Questions Answered
     Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?
     Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?
     Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?
     Which companies are actively involved in conducting clinical trials for their therapeutic candidates?
     Which partnership models are most commonly adopted by stakeholders in this industry?
     What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?
     Who are the prominent KOLs evaluating therapies within this industry?
     What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?
     How is the current and future opportunity likely to be distributed across key market segments?


    The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:

     Drug Class
     Biologics
     Small Molecules

     Route of Administration
     Intravenous Drugs
     Oral Drugs

     Type of Soft Tissue Sarcoma
     Angiosarcoma
     Chondrosarcoma
     Liposarcoma

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Rest of the World

    The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.

     Adaptimmune
     Agios Pharmaceuticals
     Agenus
     Athenex
     Eisai
     Eli Lilly
     GlaxoSmithKline
     Karyopharm Therapeutics
     Mirati Therapeutics
     PharmaMar

    For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030 Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings. Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options. To order this 130+ slides report, which features 80+ figures, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html. Key Market Insights 70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma. Around 65% of the therapeutics are being developed as small molecules Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment. More than 50 industry and non-industry players are engaged in the soft tissue sarcoma market North America has emerged as a key hub, featuring the presence of close to 60% developers. The developer landscape is further dominated by players that have been established after 1990, representing around 45% of the total number of stakeholders. Around 190 trials, evaluating therapies for soft tissue sarcoma, have been registered More than 22,000 patients have been enrolled in clinical research initiatives aimed to validate the efficacy and safety of soft tissue sarcoma targeting therapeutics. Interestingly, 60% of the overall trials are phase II studies; of these, 50% are currently active. Partnership activity in this field has increased at a CAGR of 70%, between 2018 and 2020 About 80% of the reported deals were established in the last three years, with the maximum activity being reported in 2020. Majority of the instances captured in the report were licensing agreements (45%). Further, more than 50% of the agreements were observed to be signed for therapeutics targeting liposarcoma. More than 260 articles have been published related to soft tissue sarcoma, since January 2021 Around 40% publications mentioned in the report were focused on the assessment of therapeutics that have been / are being developed for the treatment of angiosarcoma. Example of prominent journals include (in decreasing order of number of publications) BMJ Case Rep, Skeletal Radiol, Ann Surg Oncol and Cureus. Around 75 eminent scientists were identified as key opinion leaders (KOLs) 65% of these KOLs were observed to be associated with organizations based in North America, followed by those affiliated to institutes in Europe (30%) and Asia-Pacific (5%). Further, majority (50%) of the KOLs are currently affiliated to academic institutes, such as schools and universities. North America is anticipated to capture over 70% of the global market share in 2030 In 2030, nearly 80% of the market revenues are expected to be generated from sales of therapeutics that intended for the treatment of liposarcoma. Further, therapies designed for intravenous administration are expected to occupy a larger share (60%) of the overall market in 2030. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of soft tissue sarcoma targeting therapeutics?  Which is the most popular type of soft tissue sarcoma, based on the ongoing activity in the market?  Which are the most common routes of administration for soft tissue sarcoma targeting therapeutics?  Which companies are actively involved in conducting clinical trials for their therapeutic candidates?  Which partnership models are most commonly adopted by stakeholders in this industry?  What is the evolving trend related to the focus of publications related to soft tissue sarcoma targeting therapeutics?  Who are the prominent KOLs evaluating therapies within this industry?  What opportunities are available for soft tissue sarcoma targeting therapeutics in emerging markets?  How is the current and future opportunity likely to be distributed across key market segments? The USD 421 million (by 2030) financial opportunity within the soft tissue sarcoma targeting therapeutics market has been analyzed across the following segments:  Drug Class  Biologics  Small Molecules  Route of Administration  Intravenous Drugs  Oral Drugs  Type of Soft Tissue Sarcoma  Angiosarcoma  Chondrosarcoma  Liposarcoma  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes profiles of key players (listed below); each profile features a brief overview of company, pipeline details, recent developments (including collaborations and expansions) and an informed future outlook.  Adaptimmune  Agios Pharmaceuticals  Agenus  Athenex  Eisai  Eli Lilly  GlaxoSmithKline  Karyopharm Therapeutics  Mirati Therapeutics  PharmaMar For additional details, please visit https://www.rootsanalysis.com/reports/soft-tissue-sarcoma-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 3. Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The CAR-T therapies market is characterized by a healthy pipeline of promising therapies

    Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

    Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

    To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Key Market Insights

    Over 755 CAR-T cell therapies are currently approved / under development
    Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

    Currently, the focus is on developing product candidates to treat various types of cancers
    Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

    Extensive efforts are underway to improve CAR constructs
    Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
    In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

    Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
    More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

    Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
    It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

    The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
    Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

    Key Questions Answered
     Who are the leading industry and non-industry players in this market?
     What are the prevalent R&D trends in CAR-T cell therapies domain?
     What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
     What are the challenges faced by stakeholders in this industry?
     Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What kind of contract manufacturing support is available for CAR-T cell therapies?
     What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?


    The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

     Disease indication
     Non-Hodgkin lymphoma
     Multiple myeloma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Target antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
     Tim Oldham (Chief Executive Officer, Cell Therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

    The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Noile-Immune Biotech
     Novartis
     Shanghai Genechem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CAR-T therapies market is characterized by a healthy pipeline of promising therapies Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity. To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Key Market Insights Over 755 CAR-T cell therapies are currently approved / under development Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. Currently, the focus is on developing product candidates to treat various types of cancers Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications. Extensive efforts are underway to improve CAR constructs Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide. China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field. Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020 More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%). Over USD 13 billion has been invested by both private and public investors, across more than 205 instances It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%). The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players in this market?  What are the prevalent R&D trends in CAR-T cell therapies domain?  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?  What are the challenges faced by stakeholders in this industry?  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What kind of contract manufacturing support is available for CAR-T cell therapies?  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:  Disease indication  Non-Hodgkin lymphoma  Multiple myeloma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Target antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:  Tim Oldham (Chief Executive Officer, Cell Therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai Genechem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis

    Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes.

    For additional details, please visit
    https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html
    The CD-47 targeting therapeutics market is projected to grow at a CAGR of 42.9%, claims Roots Analysis Upon realizing the potential of this novel target, industry stakeholders have initiated several R&D efforts focused on exploiting the use of CD47 as an effective biomarker for the diagnosis and treatment purposes. For additional details, please visit https://www.rootsanalysis.com/reports/cd-47-targeting-therapeutics-market.html
    CD-47 Targeting Therapeutics | Industry Analysis | Market Size | 2030
    CD-47 Targeting Therapeutics Market report features an extensive study of the current market...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030

    Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria

    Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market” report to its list of offerings.

    Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options.

    To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html.

    Key Market Insights

    15+ therapies have been / are being developed for the different type of porphyria
    Treatment.
    More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria.

    Around 50% of the therapeutics are being developed as biologics
    Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria.

    Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria
    More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/porphyria-pipline-review/request-sample.html

    Key Questions Answered
     What are the prevalent R&D trends related to Porphyria?
     What are the key challenges faced by stakeholders engaged in this domain?
     What are the principal therapies developed by the companies in this domain?
     Who are the leading industry and non-industry players in this market?
     What are the key geographies where research on porphyria is actively being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?

    For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030
    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030 Several novel and innovative therapeutic approaches, both small molecule and biologics, are being currently investigated at various phases of development in order to avoid the beginning of disease-induced attacks and other long-term effects of porphyria Roots Analysis has announced the addition of “Porphyria Targeting Therapies Market” report to its list of offerings. Porphyria is a rare disorder that is characterized by excessive accumulation of porphyrin, a compound that aids in the formation of heme (an essential part of hemoglobin that helps carry oxygen in blood). Any anomaly caused by genetic or acquired abnormalities in heme biosynthesis (produced majorly in bone marrow and liver) can result in toxicity. It is worth highlighting that, till date, more than 1,000 mutations that can cause porphyria have been identified. However, prevalence of porphyria still remains unknown. Several treatment options such as gene therapy, proteasome inhibition and pharmacologic chaperones are currently being investigated among various other targeted treatment options. To order this 130+ slides report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html. Key Market Insights 15+ therapies have been / are being developed for the different type of porphyria Treatment. More than 70% of the aforementioned candidates are currently under clinical evaluation. Further, three therapies, namely Panhematin™, GIVLAARI® and SCENESSE®, have already been approved for the treatment of different types of porphyria. Around 50% of the therapeutics are being developed as biologics Majority (over 65%) of the abovementioned biologic drugs have been / are being designed for administration via the intravenous route. Furthermore, majority of the drugs (37%) have been / are being targeting acute intermittent porphyria. Over 30% of the therapies have been / are being developed for erythropoietic protoporphyria More than 65% the abovementioned therapies are currently being evaluated in clinical phases. Further, around 60% of the aforementioned therapy candidates are being developed as small molecules. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/porphyria-pipline-review/request-sample.html Key Questions Answered  What are the prevalent R&D trends related to Porphyria?  What are the key challenges faced by stakeholders engaged in this domain?  What are the principal therapies developed by the companies in this domain?  Who are the leading industry and non-industry players in this market?  What are the key geographies where research on porphyria is actively being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? For additional details, please visit https://www.rootsanalysis.com/reports/porphyria-pipline-review.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 2. Soft Tissue Sarcoma: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The Future of Manufacturing: Collaborative Robots in the Factories

    The Collaborative Robots Market, 2020-2030” report features an extensive study of the potential applications, current landscape and the likely adoption of cobots across various industrial applications, over the next decade. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field.

    Cobots, also referred to as collaborative robot, are programmed to work in collaboration / cooperation with humans in a shared space or to work safely, in close proximity.
    As per the International Federation of Robotics (IFR), there are four key attributes of cobots:
     Co-existence: These cobots can work alongside humans in same workspace, however, there should not be any direct overlap in minutiae of their labor.
     Sequential Collaboration: These cobots can also work alongside the humans, however, they should not work on the same product at the same time. These cobots work either before or after the human worker in the sequence of production for a task.
     Responsive Collaboration: These cobots respond directly to the actions undertaken by the human. They are operated for executing complicated tasks.
     Co-operation: These cobots operate alongside humans and can work together on the same task in the sequence of process.

    To request sample report: https://www.rootsanalysis.com/reports/collaborative-robots-market/request-sample.html

    Owing to their collaborative nature, there is an evident increase in the adoption of cobots in the industries, where frequent and repetitive tasks have to be performed.


    To order customize report: https://www.rootsanalysis.com/reports/collaborative-robots-market/request-customization.html

    Unlike robots, cobots do not displace the manpower, instead work alongside the humans.
    Owing to their affordability and ease of programming, the future of cobots is promising; in fact, the market for such machines is expected to witness double-digit growth. It is worth highlighting those developing nations, such as China, India are also deploying automation to maintain their positions as global contract services hubs, as manual labor costs swell over time. Moreover, with the growth of industrial internet of things (IoT), increased device autonomy, rising process complexity, and evolving health and safety requirements, SMEs are likely to rely more on the cobots in the next 4-5 years. Having said that, we are led to believe that cobots are likely to offer lucrative business opportunities to the stakeholders working in this domain.

    For more information, please click on the following link: https://www.rootsanalysis.com/reports/collaborative-robots-market.html

    You may also be interested in the following reports:
    1. Myeloid Cells Targeting Therapeutics Market
    2. ADC Cytotoxic Payloads
    3. Large Volume Wearable Injectors Market
    4. Dry Age-related Macular Degeneration Market

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The Future of Manufacturing: Collaborative Robots in the Factories The Collaborative Robots Market, 2020-2030” report features an extensive study of the potential applications, current landscape and the likely adoption of cobots across various industrial applications, over the next decade. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Cobots, also referred to as collaborative robot, are programmed to work in collaboration / cooperation with humans in a shared space or to work safely, in close proximity. As per the International Federation of Robotics (IFR), there are four key attributes of cobots:  Co-existence: These cobots can work alongside humans in same workspace, however, there should not be any direct overlap in minutiae of their labor.  Sequential Collaboration: These cobots can also work alongside the humans, however, they should not work on the same product at the same time. These cobots work either before or after the human worker in the sequence of production for a task.  Responsive Collaboration: These cobots respond directly to the actions undertaken by the human. They are operated for executing complicated tasks.  Co-operation: These cobots operate alongside humans and can work together on the same task in the sequence of process. To request sample report: https://www.rootsanalysis.com/reports/collaborative-robots-market/request-sample.html Owing to their collaborative nature, there is an evident increase in the adoption of cobots in the industries, where frequent and repetitive tasks have to be performed. To order customize report: https://www.rootsanalysis.com/reports/collaborative-robots-market/request-customization.html Unlike robots, cobots do not displace the manpower, instead work alongside the humans. Owing to their affordability and ease of programming, the future of cobots is promising; in fact, the market for such machines is expected to witness double-digit growth. It is worth highlighting those developing nations, such as China, India are also deploying automation to maintain their positions as global contract services hubs, as manual labor costs swell over time. Moreover, with the growth of industrial internet of things (IoT), increased device autonomy, rising process complexity, and evolving health and safety requirements, SMEs are likely to rely more on the cobots in the next 4-5 years. Having said that, we are led to believe that cobots are likely to offer lucrative business opportunities to the stakeholders working in this domain. For more information, please click on the following link: https://www.rootsanalysis.com/reports/collaborative-robots-market.html You may also be interested in the following reports: 1. Myeloid Cells Targeting Therapeutics Market 2. ADC Cytotoxic Payloads 3. Large Volume Wearable Injectors Market 4. Dry Age-related Macular Degeneration Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Global Collaborative Robots (Cobots) Market: Medical Robots | Industry Analysis | Market Size | 2030
    Adoption of collaborative robots (cobots) is expected to increase by ten fold, the market is likely to witness 30.7% annualized growth
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The medical device batteries market is projected to grow at an annualized rate of 12%

    An exponential increase in development efforts related to wearable medical devices and implants, has fueled a corresponding rise in demand for safe, compact, light-weight and high energy density batteries with longer life span

    Roots Analysis has announced the addition of “Medical Device Batteries: Focus on Implants and Wearable Medical Devices - Market Distribution by Battery Chemistry (Lithium, Zinc Air, Nickel and Others), Rechargeability (Rechargeable and Non-Rechargeable), Application (Hearing Aids, Patient Monitoring Devices, Drug Delivery Devices, Cardiovascular Medical Devices and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings.

    Battery-operated medical devices, such as cochlear implants, defibrillators, insulin pumps and pacemakers, have redefined 21st century healthcare, adding to the user convenience factor and offering profitable value propositions for developers. Battery technologies have simultaneously evolved, with modern power-storage cells having improved safety features and the potential to be used for longer durations.

    To order this 190+ page report, which features 60+ figures and 90+ tables, please visit this - https://www.rootsanalysis.com/reports/medical-device-batteries-market.html

    Key Market Insights

    More than 930 batteries, designed for use in medical devices, are currently available / under development
    More than 75% of the aforementioned batteries that are intended for implants and wearable medical devices, have lithium based chemistries. The majority of batteries captured in the report (62%) are intended for hearing aids; this is followed by those used in patient monitoring devices (17%) and drug delivery devices (12%).

    Over 50 companies, across the world, claim to be engaged in developing medical device batteries
    Majority (45%) of these battery developers are located in the Asia Pacific region, primarily in China, while Europe (29%) and North America (27%) almost have an equal number of innovators focused in this field. More than 40% of the industry stakeholders are very large firms.

    330+ patents related to medical device batteries have been filed since 2015
    R&D activity related to medical device batteries is largely concentrated in the US, considering that more than 35% of the total number of patents were filed in this region. Around 70% of intellectual property related filings in this field were observed to focused on batteries intended for implantable devices.

    North America and Europe are anticipated to capture close to 50% market share, by 2030
    On the other hand, Asia Pacific is expected to witness a higher growth rate as compared to other geographies due to the advancement in healthcare facilities. Currently, the market is driven by the sales of medical device batteries designed for wearable medical devices (75%), followed by those intended to power implantable devices (25%). Further, rechargeable medical device batteries currently capture 25% of the overall market share (in terms of sales revenues).

    To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/medical-device-batteries-market/request-sample.html

    Key Questions Answered
     What kind of batteries are currently available / under development for different types of medical devices?
     Who are the leading developers of medical device batteries?
     What are the key applications of medical device batteries in the modern healthcare industry?
     Who are the most likely partners for medical device battery developers?
     How is the intellectual property landscape in this field likely to evolve in the foreseen future?
     What are the factors that are likely to influence the market’s evolution?
     How is the current and future opportunity likely to be distributed across key market segments?

    The USD XX billion (by 2030) financial opportunity within the medical device batteries market has been analyzed across the following segments:
     Battery Chemistry
     Lithium based
     Zinc Air based
     Nickel based
     Others

     Type of Device
     Implantable
     Wearable

     Rechargeability
     Rechargeable
     Non-Rechargeable

     Application
     Hearing Aids
     Patient Monitoring Devices
     Drug Delivery Devices
     Cardiovascular Medical Devices
     Others

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The research includes detailed profiles of key players (listed below) engaged in the development of medical device batteries; each profile features an overview of the developer, its financial information (if available), recent developments and an informed future outlook.
     Blue Spark Technologies
     CAMELION
     EaglePicher Technologies
     Energizer Holdings
     Guangzhou Battsys
     Murata
     Panasonic
     Renata
     Tadiran Batteries
     Toshiba
     Ultralife
     VARTA Microbattery

    For additional details, please visit https://www.rootsanalysis.com/reports/medical-device-batteries-market.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030
    2. Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030
    3. Inhaled and Intranasal Products Contract Service Providers Market by Product Manufacturing Services (API Manufacturing, End Product Manufacturing and Others), Drug Delivery System (Metered Dose Inhaler, Dry Powder Inhaler, Nebulizer and Nasal Spray), Route of Administration (Orally Inhaled and Intranasal), Scale of Operation (Clinical, Commercial and Both) and Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2020-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The medical device batteries market is projected to grow at an annualized rate of 12% An exponential increase in development efforts related to wearable medical devices and implants, has fueled a corresponding rise in demand for safe, compact, light-weight and high energy density batteries with longer life span Roots Analysis has announced the addition of “Medical Device Batteries: Focus on Implants and Wearable Medical Devices - Market Distribution by Battery Chemistry (Lithium, Zinc Air, Nickel and Others), Rechargeability (Rechargeable and Non-Rechargeable), Application (Hearing Aids, Patient Monitoring Devices, Drug Delivery Devices, Cardiovascular Medical Devices and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2020-2030” report to its list of offerings. Battery-operated medical devices, such as cochlear implants, defibrillators, insulin pumps and pacemakers, have redefined 21st century healthcare, adding to the user convenience factor and offering profitable value propositions for developers. Battery technologies have simultaneously evolved, with modern power-storage cells having improved safety features and the potential to be used for longer durations. To order this 190+ page report, which features 60+ figures and 90+ tables, please visit this - https://www.rootsanalysis.com/reports/medical-device-batteries-market.html Key Market Insights More than 930 batteries, designed for use in medical devices, are currently available / under development More than 75% of the aforementioned batteries that are intended for implants and wearable medical devices, have lithium based chemistries. The majority of batteries captured in the report (62%) are intended for hearing aids; this is followed by those used in patient monitoring devices (17%) and drug delivery devices (12%). Over 50 companies, across the world, claim to be engaged in developing medical device batteries Majority (45%) of these battery developers are located in the Asia Pacific region, primarily in China, while Europe (29%) and North America (27%) almost have an equal number of innovators focused in this field. More than 40% of the industry stakeholders are very large firms. 330+ patents related to medical device batteries have been filed since 2015 R&D activity related to medical device batteries is largely concentrated in the US, considering that more than 35% of the total number of patents were filed in this region. Around 70% of intellectual property related filings in this field were observed to focused on batteries intended for implantable devices. North America and Europe are anticipated to capture close to 50% market share, by 2030 On the other hand, Asia Pacific is expected to witness a higher growth rate as compared to other geographies due to the advancement in healthcare facilities. Currently, the market is driven by the sales of medical device batteries designed for wearable medical devices (75%), followed by those intended to power implantable devices (25%). Further, rechargeable medical device batteries currently capture 25% of the overall market share (in terms of sales revenues). To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/medical-device-batteries-market/request-sample.html Key Questions Answered  What kind of batteries are currently available / under development for different types of medical devices?  Who are the leading developers of medical device batteries?  What are the key applications of medical device batteries in the modern healthcare industry?  Who are the most likely partners for medical device battery developers?  How is the intellectual property landscape in this field likely to evolve in the foreseen future?  What are the factors that are likely to influence the market’s evolution?  How is the current and future opportunity likely to be distributed across key market segments? The USD XX billion (by 2030) financial opportunity within the medical device batteries market has been analyzed across the following segments:  Battery Chemistry  Lithium based  Zinc Air based  Nickel based  Others  Type of Device  Implantable  Wearable  Rechargeability  Rechargeable  Non-Rechargeable  Application  Hearing Aids  Patient Monitoring Devices  Drug Delivery Devices  Cardiovascular Medical Devices  Others  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The research includes detailed profiles of key players (listed below) engaged in the development of medical device batteries; each profile features an overview of the developer, its financial information (if available), recent developments and an informed future outlook.  Blue Spark Technologies  CAMELION  EaglePicher Technologies  Energizer Holdings  Guangzhou Battsys  Murata  Panasonic  Renata  Tadiran Batteries  Toshiba  Ultralife  VARTA Microbattery For additional details, please visit https://www.rootsanalysis.com/reports/medical-device-batteries-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global Handheld X-Ray Imaging Devices Market by Area of Application (Dental and Others), Device Class (Low-End, Mid-End and High-End), End-Users (Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, Specialty Clinics and Others), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle-East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2020-2030 2. Diabetes Monitoring Devices Market by Type of Device (Self-Monitoring Blood Glucose Devices and Continuous Blood Glucose Monitoring Devices), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Type of Self-Monitoring Blood Glucose Device Component (Lancing Devices, Blood Glucose Meters and Testing Strips), Type of Continuous Blood Glucose Monitoring Device Component (Sensors, Transmitters and Receivers), and Key Geographies: Industry Trends and Global Forecasts, 2020-2030 3. Inhaled and Intranasal Products Contract Service Providers Market by Product Manufacturing Services (API Manufacturing, End Product Manufacturing and Others), Drug Delivery System (Metered Dose Inhaler, Dry Powder Inhaler, Nebulizer and Nasal Spray), Route of Administration (Orally Inhaled and Intranasal), Scale of Operation (Clinical, Commercial and Both) and Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Medical Device Batteries Market | Industry Analysis | Market Size | 2030
    The Medical Device Batteries Market, 2020-2030 report features an extensive study of the current market landscape and future potential of medical device...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored